• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

    8/12/25 9:05:53 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Janux Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    47103J105

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    47103J105


    1Names of Reporting Persons

    Adage Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,525,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,525,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.27 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    47103J105


    1Names of Reporting Persons

    Robert Atchinson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,525,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,525,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.27 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    47103J105


    1Names of Reporting Persons

    Phillip Gross
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,525,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,525,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.27 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Janux Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    10955 Vista Sorrento Parkway, Suite 200 San Diego, CA 92130
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock") of Janux Therapeutics, Inc., a Delaware corporation (the "Company") directly held by ACP; (ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and (iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
    (c)Citizenship:

    ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    47103J105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 59,175,157 shares of Common Stock outstanding as of May 6, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025.
    (b)Percent of class:

    4.27%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Adage Capital Management, L.P.
     
    Signature:/s/ Robert Atchinson
    Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
    Date:08/12/2025
     
    Robert Atchinson
     
    Signature:/s/ Robert Atchinson
    Name/Title:Robert Atchinson, individually
    Date:08/12/2025
     
    Phillip Gross
     
    Signature:/s/ Phillip Gross
    Name/Title:Phillip Gross, individually
    Date:08/12/2025
    Get the next $JANX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    8/19/2025$42.00Overweight
    Piper Sandler
    7/11/2025$65.00Outperform
    Raymond James
    12/3/2024$82.00 → $100.00Buy
    BTIG Research
    12/3/2024$63.00 → $70.00Buy
    H.C. Wainwright
    11/22/2024$79.00Outperform
    Leerink Partners
    10/24/2024$69.00Buy
    UBS
    9/6/2024$70.00Buy
    Stifel
    5/30/2024$47.00Sector Perform
    Scotiabank
    More analyst ratings

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. was granted 3,750 shares (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    6/13/25 7:33:08 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dobmeier Eric was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    6/13/25 7:30:18 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gujrathi Sheila was granted 3,750 shares, increasing direct ownership by 3% to 118,889 units (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    6/13/25 7:30:17 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Janux Therapeutics with a new price target

    Piper Sandler initiated coverage of Janux Therapeutics with a rating of Overweight and set a new price target of $42.00

    8/19/25 8:34:16 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Janux Therapeutics with a new price target

    Raymond James initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $65.00

    7/11/25 8:13:15 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research reiterated coverage on Janux Therapeutics with a new price target

    BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously

    12/3/24 7:52:53 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

    SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    8/14/25 11:26:39 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

    SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    8/12/25 9:05:53 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Janux Therapeutics Inc.

    10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)

    8/7/25 4:22:14 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    10/22/24 4:20:04 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    11/15/23 4:48:17 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

    R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 First patient dosed in lead collaboration program triggers $10 million milestone payment from Merck $996.0 million in cash, cash equivalents, and short-term investments at end of second quarter 2025 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRA

    8/7/25 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

    First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada. Under the terms of the collaboration that was entered in December 2020, Janux is eligible to receive development and com

    8/5/25 4:05:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

    PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

    7/24/25 4:05:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Financials

    Live finance-specific insights

    View All

    Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

    Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

    7/17/23 8:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:24:38 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:17:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:01:49 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    View All

    Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

    PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

    7/24/25 4:05:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

    7/17/25 4:30:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

    Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

    5/15/25 8:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care